CliffBio
biologic

Kineret

anakinra

Loss of exclusivityNovember 2013projected — 12-year biologic exclusivity estimate
CompanySwedish Orphan Biovitrum AB (publ)

Drug detail

Brand nameKineret
Active ingredientanakinra
Strength100MG/0.67ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalNovember 2001
Marketing statusRx

More from Swedish Orphan Biovitrum AB (publ)

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Kineret patent cliff — loss of exclusivity November 2013 | CliffBio